Prognostic markers of local relapse in rectal cancer: are we any further forward?
Johnston
Patrick G
PG
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism*; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005472:Fluorouracil / Q000008:administration & dosage / Q000378:metabolism; D020869:Gene Expression Profiling; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008207:Lymphatic Metastasis; D020360:Neoadjuvant Therapy / Q000379:methods; D009364:Neoplasm Recurrence, Local / Q000201:enzymology / Q000473:pathology* / Q000517:prevention & control*; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D016032:Randomized Controlled Trials as Topic; D012004:Rectal Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000473:pathology* / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D013940:Thymidylate Synthase / Q000378:metabolism
D014408:Biomarkers, Tumor; D013940:Thymidylate Synthase; D005472:Fluorouracil